FDA Approves Opus Genetics' Presbyopia Drop, Management Projects Runway to 2029

What happened

Opus Genetics announced FDA approval for its presbyopia eye drop, likely triggering milestone and royalty provisions under the Viatris license agreement, and management used an investor panel to lay out commercialization expectations and a funding strategy that extends cash runway to 2029. The approval addresses a previously disclosed sNDA with an anticipated decision by end-2026, arriving earlier than expected and providing a partnered revenue stream alongside existing RYZUMVI royalties. However, the company remains a clinical-stage gene therapy developer with LCA5 Phase 3 dosing still gated by validated commercial-process supply, and the presbyopia product's commercial ramp will be controlled by Viatris, limiting Opus's direct control over cash generation. The projected runway to 2029 contrasts with previously filed minimum-runway language of at least twelve months beyond November 2025 and a reported cash balance of $30.8 million as of September 2025, implying either significantly reduced burn or substantial non-dilutive inflows that have not yet been audited. Investors should view the approval as a positive but not transformative event until concrete revenue and CMC progress materialize.

Implication

The FDA approval adds a potentially recurring royalty stream, but Viatris controls commercialization, and Opus's ability to extend runway to 2029 depends on successful launch and partner economics that are not yet proven. Core value remains tied to OPGx-LCA5, where Phase 3 dosing is contingent on validated commercial-process supply, a milestone that has not been de-risked. The company's cash burn of $25.4 million over nine months and open ATM facility suggest dilution risk persists unless presbyopia revenues ramp quickly or non-dilutive funding is secured. Management's runway claim should be reconciled with future quarterly filings to confirm reduced operating cash use. Maintain a wait-and-see stance, with potential to add on a pullback toward the $2.40 attractive entry or after concrete CMC and commercial traction signals.

Thesis delta

Previous thesis was WAIT due to CMC gating for LCA5 and financing uncertainty. The presbyopia approval introduces a partnered revenue product that could modestly offset burn, but does not remove the critical manufacturing validation required for LCA5 Phase 3 dosing in 2H26. The thesis shifts from a pure binary gene therapy bet to a hybrid with a marketed asset, but conviction remains low until commercialization and supply milestones are demonstrated.